Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Investor Presentation (June 2015)
23 slides from Proteomics International Laboratories's investor presentation, Jun 10, 2015
Slide 1: Proteomics International Laboratories Ltd Investor Presentation June 2015
Proteomics International Laboratories Ltd For personal use only Investor Presentation | June 2015 Global leader & innovator in the field of proteomics ASX: PIQ 1 Proteomics International Laboratories Limited
Slide 2: Disclaimer and Forward looking statements
Disclaimer and Forward looking statements For personal use only This Presentation is provided by Proteomics International Laboratories Ltd (the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deci
Slide 3: Positioning Statement
For personal use only Positioning Statement The Human Genome Project, to map human DNA, is the single largest undertaking in the history of biological science. Led by the US government, it was a $US3 billion international collaboration completed in 2003 after almost two decades of planning and execu
Slide 4: What is proteomics?
What is proteomics? For personal use only Proteomics is the industrial scale study of the structure and function of proteins. It is an integral part of the biotechnology and life sciences industries and plays a key role in understanding disease and biological systems. Represents a massive global mar
Slide 5: Corporate Overview
Corporate Overview For personal use only Capital Structure Shareholders ASX code PIQ Top 20 Shareholders 70.59% Shares on issue ~50.6m Major Shareholders Listed 16 April 2015 Richard Lipscombe XYLO Pty Ltd Market capitalisation (@71c) ~A$36m John Dunlop 12 month price range 77.5c-18.5c Randolph Reso
Slide 6: Board & Management
Board & Management For personal use only Terry Sweet FAICD, Chairman Director of several listed companies over the past 30 years in both executive and non-executive capacities Companies include XRF Scientific Ltd, where he was Managing Director for 4 years, Western Biotechnology Ltd, Heartlink Ltd,
Slide 7: Company Overview
Company Overview For personal use only Established, revenue generating Company – Established 2001 Global leader & innovator in field of proteomics World’s first company to receive ISO 17025 laboratory accreditation for proteomics services Proven technology with established IP Operates from purpose b
Slide 8: Growth markets
Growth markets For personal use only Diagnostics (biomarkers) market is $17.5b predicted to reach $40.8b by 2018 'omics technology holds ~75% share Proteomics market to be $20.8b by 2018 Bio-engineered protein drugs was $152b (2013) CAGR 7.2% 7 of world's top 10 selling drugs were proteins therapeut
Slide 9: Proprietary Platform Technology
Proprietary Platform Technology For personal use only One proven and proprietary platform, multiple uses: biomarker discovery, biosimilars testing, drug discovery The methodology was developed as part of a $6.5m self-funded R&D program 9 Proteomics International Laboratories Limited
Slide 10: Business model
Business model For personal use only Three synergistic business units Unifying platform technology Existing revenue generation & deal flow... Multiple major upside opportunities 10 Proteomics International Laboratories Limited
Slide 11: Diagnostics
For personal use only Diagnostics Core component of the Company’s operations; focuses on utilising its proteomics-based technology platform to discover new diagnostic tests based on differences in protein make-up of people with and without a particular disease. PIQ can produce a set of biomarkers to
Slide 12: Predictive test for diagnosis of Diabetic Kidney Disease
Predictive test for diagnosis of Diabetic Kidney Disease For personal use only Company has developed and validated the world’s first proteomics-derived predictive (prognostic) test for the diagnosis of diabetic kidney disease (DKD). Test, called PromarkerD, is a global breakthrough in the diagnosis
Slide 13: Predictive DKD test – Market potential
Predictive DKD test – Market potential For personal use only Commercial benefits, medical benefits and cost savings in commercialising the test are substantial - in Australia alone, total cost to health system and in productivity loss from diabetes estimated at $10.3b annually. International Diabete
Slide 14: Predictive DKD test – Background
Predictive DKD test – Background For personal use only Test developed using PIQ's proteomics platform to measure specific biomarkers (biological signatures) in the blood of patients with diabetes to determine the likelihood of those patients contracting DKD. Test was developed & validated in a $2m c
Slide 15: Chinese Market
Chinese Market For personal use only Agreement with major Chinese biopharmaceutical company, Newsummit Biopharma Co., to commercialise the test in China. Agreement is PIQ’s first commercial agreement for the test. Under the Agreement, PIQ is working with New Summit Bio to manufacture the test kit an
Slide 16: Additional Diagnostic Targets
Additional Diagnostic Targets For personal use only Other diabetes complications Heart disease Loss of eye sight Poor circulation leading to amputations Alzheimer's disease In the USA, one-in-nine people over 65 suffer from the condition Annual cost of caring for Alzheimer's patients estimated at $2
Slide 17: Analytical Services
For personal use only Analytical Services PIQ’s Analytical Services business is built around its proteomics technology platform’s ability to test & validate the protein composition of a wide and varied range of products. It has major application in the generic drug market (bio-similars) with manufac
Slide 18: Analytical Services
Analytical Services For personal use only Proven track record in analysing protein drugs Blue chip, global client base. Analytical & consulting services growing >30% per year. PIQ is one of the few companies worldwide with international accreditation. Latest US FDA guidance (May 2014) for biosimilar
Slide 19: Analytical Services – Clients & partners
Analytical Services – Clients & partners For personal use only An array of blue chip, international clients and partners have contributed to a growing client base and sustained income for 14 consecutive years 19 Proteomics International Laboratories Limited
Slide 20: Proteomics sector transactions
Proteomics sector transactions For personal use only Proteome Sciences (AIM: PRM) biomarker discovery, validation and assay development in Alzheimer's, breast cancer & cosmetics revenue up 86% in 2013 to GBP2.14m; mkt cap $100.8m (1 Feb 15) Applied Proteomics Inc, private San Diego-based company bio
Slide 21: Sector transactions
Sector transactions For personal use only Year Target Buyer / Details Financials Licensor 2012 Cellzome Glaxo Cellzome’s proteomics technologies Total buyout - $99m SmithKline used in drug discovery in cells and patient samples 2012 Kforce inVentiv Health Functional outsourcing and CRO Total buyout
Slide 22: Intellectual property
Intellectual property For personal use only PILL protects its know-how and expertise to ensure it remains a substantial source of competitive advantage All biomarker and drug leads discovered using the platform technology will be protected by global patenting as a prerequisite for out-licensing acti
Slide 23: Please contact
Please contact For personal use only Richard Lipscombe Managing Director, Proteomics International Laboratories Limited M: +61 414 405 631 E: r.lipscombe@proteomicsinternational.com T: +61 8 9389 1992 www.ProteomicsInternational.com Chuck Morrison Head of Business Development T: +1 617 331 2975 E: c
Proteomics International Laboratories — Investor Presentation (June 2015) on 6ix